Ebola

Appili Therapeutics Provides Enrollment Update for Its Phase 3 PRESECO Trial Evaluating the Oral Antiviral Favipiravir as an Early Treatment in COVID-19

Retrieved on: 
Thursday, January 28, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Chemistry, Chemical compounds, Physical sciences, COVID-19, Ebola, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, Coronavirus disease, Antiviral drug, Draft:Zhejiang Hisun Pharmaceutical, Appili’s Phase 3 PRESECO Clinical Trial, Favipiravir, Appili Therapeutics

PRESECO is evaluating favipiravir, an oral antiviral, in the early treatment of COVID-19 in the outpatient setting.

Key Points: 
  • PRESECO is evaluating favipiravir, an oral antiviral, in the early treatment of COVID-19 in the outpatient setting.
  • Our PRESECO study is designed to answer the critical question, does favipiravir work for COVID-19 patients early in the outpatient setting?
  • Appili plans to prioritize its resources to accelerate recruitment and data analysis for the PRESECO study.
  • As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral favipiravir for the worldwide treatment and prevention of COVID-19.

 ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spread

Retrieved on: 
Tuesday, January 19, 2021
Health, Other Science, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Vaccines, Medicine, Health sciences, Health, Medical research, Clinical research, COVID-19 vaccine, Clinical trials, Ebola, Vaccine trial, the T-Cell-Based Vaccine Candidate, ImmunityBio, NantKwest

The same vaccine is currently being tested in a similar Phase I trial in the U.S., with no safety concerns identified to date.

Key Points: 
  • The same vaccine is currently being tested in a similar Phase I trial in the U.S., with no safety concerns identified to date.
  • These exciting results have catalyzed our interest in pursuing human trials of the oral vaccine in South Africa.
  • Understanding sensitivities related to adeno vaccine platforms in South Africa, we have taken the utmost care in designing our trial, said Dr. Amy Ward, principal investigator of the Phase I trial.
  • ImmunityBio has engaged with government agencies and indicated a commitment to ensuring this vaccine is available in South Africa.

Oyagen, Inc. Publishes Study On Its OYA1 As A "Highly Effective" Experimental Drug Candidate For Treating Infections By The Ebola Virus

Retrieved on: 
Thursday, January 7, 2021
Medical specialties, Medicine, Clinical medicine, Zoonoses, Tropical diseases, Ebola, Biological weapons, West African Ebola virus epidemic, Virus, Zaire ebolavirus, Infection, Ebola virus disease treatment research

This Study identified OYA1 as a "highly effective" antiviral against several viruses including Ebola and Lassa viruses.

Key Points: 
  • This Study identified OYA1 as a "highly effective" antiviral against several viruses including Ebola and Lassa viruses.
  • The published study results showed that OYA1 was "highly effective" in reducing the spread of Ebola Virus infection in laboratory tests with the live Ebola virus carried out by NIAID.
  • OYA1 proved equally effective in stopping Ebola infectivity when it was added at the time of infection or 24 hours after an infection.
  • OYA1 was abandoned as a drug candidate for cancer because it had no effect in reducing tumor burden.

CDC 2020 in Review

Retrieved on: 
Tuesday, December 29, 2020
Medical specialties, Infectious diseases, Medicine, Zoonoses, Ebola, Health in Africa, Vitamin E, Kivu Ebola epidemic, Équateur province Ebola outbreak

In February 2020, CDC published its definitive study on the lung fluid findings, which confirmed the association between vitamin E acetate and EVALI, in the New England Journal of Medicine.

Key Points: 
  • In February 2020, CDC published its definitive study on the lung fluid findings, which confirmed the association between vitamin E acetate and EVALI, in the New England Journal of Medicine.
  • And CDC was there again for the three back-to-back outbreaks DRC experienced from 2018 to 2020.
  • In 2020, CDC was part of the global public health response to two Ebola outbreaks in DRC.
  • The second was announced on June 1, 2020 in Equateur Province and declared over on November 18, 2020 .

Ridgeback Biotherapeutics LP Announces the Approval of EbangaTM for Ebola

Retrieved on: 
Tuesday, December 22, 2020
Biotechnology, FDA, Infectious diseases, Health, Pharmaceutical, Medical specialties, Infectious diseases, Viral diseases, Antiviral drugs, Molnupiravir, West African Ebola virus epidemic, Ebola, Food and Drug Administration, MAb114, Ebanga, Ridgeback Biotherapeutics LP

Ridgeback Biotherapeutics LP (Ridgeback), a biotechnology company experienced in antiviral drug development, announced today that the U.S. Food and Drug Administration (FDA) approved EbangaTM for the treatment of Ebola.

Key Points: 
  • Ridgeback Biotherapeutics LP (Ridgeback), a biotechnology company experienced in antiviral drug development, announced today that the U.S. Food and Drug Administration (FDA) approved EbangaTM for the treatment of Ebola.
  • It was their mission to create a lyophilized single-use Ebola treatment, and in partnership with the team at Ridgeback, that vision became a reality.
  • In 2020, Ridgeback initiated a compassionate use protocol for Ebola patients during the DRCs 11th Ebola outbreak in quateur Province.
  • Ridgeback markets EbangaTM for the treatment of Ebola and has a late-stage development pipeline which includes molnupiravir for the treatment of COVID-19.

BioCryst Provides Update on Galidesivir Program

Retrieved on: 
Tuesday, December 22, 2020
Antiviral drugs, Nucleosides, Ebola, Galidesivir, Biology, Life sciences, Medical specialties, Biodefense, National Institute of Allergy and Infectious Diseases, Broad-spectrum antiviral drug, BioCryst Pharmaceuticals

We are encouraged by the first patient data with galidesivir and the growing body of evidence that galidesivir could be an important broad-spectrum antiviral.

Key Points: 
  • We are encouraged by the first patient data with galidesivir and the growing body of evidence that galidesivir could be an important broad-spectrum antiviral.
  • We appreciate the governments continued investment to investigate galidesivir as a biodefense drug, said Jon Stonehouse, chief executive officer of BioCryst.
  • BioCryst is engaged in ongoing discussions with NIAID to define specific further galidesivir studies that NIAID would support.
  • This press release contains forward-looking statements, including statements regarding BioCrysts plans and expectations for its galidesivir development program.

Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS™ (favipiravir) Tablets for the Treatment of COVID-19 under Health Canada’s Interim Order

Retrieved on: 
Tuesday, December 22, 2020
Health, Infectious diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Chemistry, Health sciences, Physical sciences, COVID-19, Ebola, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, Coronavirus disease, COVID-19 drug repurposing research, Draft:Zhejiang Hisun Pharmaceutical, Dr. Reddy’s, FUJIFILM Corporation, Global Response Aid (GRA):, AiPharma:, Appili Therapeutics:

If approved, we look forward to launching this important product soon to benefit the lives and health of COVID-19 patients in Canada.

Key Points: 
  • If approved, we look forward to launching this important product soon to benefit the lives and health of COVID-19 patients in Canada.
  • Our role remains to design rigorous trials to obtain the data that identify COVID-19 patients that may benefit from REEQONUS.
  • Our outreach to Canada is a part of our global efforts to play an active role in addressing the COVID-19 situation.
  • According to Health Canada, REEQONUS (favipiravir) Tablets are the first oral solid dosage form submitted under the Interim Order.

First Patient Dosed in Appili Therapeutics’ Phase 3 Clinical Trial of Avigan® Tablets (Favipiravir) for the Treatment of COVID-19 in the United States

Retrieved on: 
Wednesday, December 2, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Health sciences, Health, Medicine, Clinical research, Pharmaceutical industry, COVID-19, Drug discovery, Ebola, Favipiravir, Management of COVID-19, Clinical trial, Coronavirus disease, Avigan (Favipiravir), Appili Therapeutics

Appili has engaged PRA Health Sciences as a clinical research organization (CRO) to administer the trial at 47 outpatient sites.

Key Points: 
  • Appili has engaged PRA Health Sciences as a clinical research organization (CRO) to administer the trial at 47 outpatient sites.
  • Appili is initially focusing the trial in the United States but may expand the program to other areas of the world affected by COVID-19.
  • Early intervention with patients before they develop severe COVID-19 and require hospitalization remains a significant unmet need in the COVID-19 treatment landscape.
  • As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan (favipiravir) for the worldwide treatment and prevention of COVID-19.

Outbreak declared over: 11th Ebola virus disease outbreak in the Democratic Republic of the Congo

Retrieved on: 
Saturday, November 21, 2020
Medical specialties, Infectious diseases, Medicine, Ebola, Biological weapons, Tropical diseases, Zoonoses, Zaire ebolavirus, Democratic Republic of the Congo, Disease outbreak, Kivu Ebola epidemic, Democratic Republic of the Congo Ebola virus outbreak

On 18 November 2020, the Minister of Health for the DRC, Eteni Longondo, followed by the World Health Organization (WHO), declared the 11th outbreak of Ebola virus disease in the DRC over.

Key Points: 
  • On 18 November 2020, the Minister of Health for the DRC, Eteni Longondo, followed by the World Health Organization (WHO), declared the 11th outbreak of Ebola virus disease in the DRC over.
  • However, the 9th Ebola outbreak occurred between May and July 2018, in the same part of the country as this most recent outbreak, and led to a total of 54 cases and 33 deaths.
  • Therefore, a combination of active and passive surveillance must be maintained for six months after the declared end of the outbreak.
  • The virus remains endemic in the region as it is present in animal reservoirs in many parts of the country.

Global WholeHealth Partners Corp. (GWHP) Announces It Now Offers the New FDA Cleared Fingerstick for Rapid COVID-19 Test Results in Minutes

Retrieved on: 
Thursday, November 5, 2020
Infectious diseases, Medical specialties, Medicine, Tropical diseases, Zoonoses, Vaccine-preventable diseases, Medical terminology, Medical tests, Ebola, Rapid diagnostic test, Malaria, Fingerstick

With the new fingerstick test, healthcare providers can prick a patients finger and get results in minutes without having to wait for venous blood.

Key Points: 
  • With the new fingerstick test, healthcare providers can prick a patients finger and get results in minutes without having to wait for venous blood.
  • On September 23, 2020, that EUA was being reissued to authorize the test for POC use using fingerstick blood samples.
  • 2260-11-2019, are tests like Rapid Ebola, Rapid Dengue Fever Antibody and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.
  • 2260-11-2019, are tests like Rapid Ebola, Rapid Dengue Fever Antibody and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.